chronic myeloid leukaemia

Showing 6 posts of 6 posts found.

Novartis’s Tasigna scores EU approval in paediatric patients

November 20, 2017
Sales and Marketing Europe, Novartis, Tasigna, chronic myeloid leukaemia, pharma

Novartis’s Tasigna (nilotinib) has received European Commission approval for the treatment of newly diagnosed Philadelphia chromosome-positive chronic myeloid leukemia in …


NICE thumbs up for BMS leukaemia treatment

November 18, 2016
Medical Communications, Sales and Marketing BMS, Bristol-Myers Squibb, NICE, Sprycel, chronic myeloid leukaemia

Bristol-Myers Squibb has announced that NICE have given a Final Appraisal Determination recommending Sprycel (dasatinib) for the treatment of chronic …


Precision medicine reveals ‘Achilles heel’ in chronic myeloid leukaemia

September 16, 2016
Medical Communications University of Glasgow, chronic myeloid leukaemia

Scientists at the University of Glasgow believe they have revealed an ‘Achilles heel’ of chronic myeloid leukaemia (CML), making their …


Helsinn and MEI Pharma join forces to develop leukaemia drug Pracinostat

August 9, 2016
Manufacturing and Production, Research and Development Helsinn, MEI Pharma, Pracinostat, chronic myeloid leukaemia

Swiss pharmaceutical group Helsinn has entered an agreement with MEI Pharma over the licensing, development and commercialisation of Pracinostat (SB939) …


NHS restriction of CML treatment in England criticised

August 27, 2015
Medical Communications, Sales and Marketing NHS, NICE, chronic myeloid leukaemia, leukaemia

Medical experts have criticised NHS cost regulators’ decision to limit the use of Ariad’s Iclusig (ponatinib) in the treatment of …

Trial hitch for Pfizer’s leukaemia drug submission plans

December 7, 2010
Research and Development, Sales and Marketing CML, Gleevec, Glivec, Pfizer, bosutinib, chronic myeloid leukaemia

Pfizer is pressing ahead with plans to submit bosutinib for European approval despite the chronic myeloid leukaemia drug missing its …

Latest content